首页 > 市场调查报告书 > 医疗设备

整形外科

关节内粘稠补充疗法市场规模、份额和成长分析（按产品、应用、来源、最终用户和地区划分）—产业预测，2025-2032年

市场调查报告书

商品编码

1878017

关节内粘稠补充疗法市场规模、份额和成长分析（按产品、应用、来源、最终用户和地区划分）—产业预测，2025-2032年

Viscosupplementation Market Size, Share, and Growth Analysis, By Product (Introduction, Single Injection), By Application (Introduction, Knee Osteoarthritis), By Source, By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年11月18日 | 出版商:

SkyQuest | 英文 183 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球关节内粘稠补充疗法市场预计到 2024 年将达到 51 亿美元，到 2025 年将达到 53.8 亿美元，到 2033 年将达到 82.6 亿美元，预测期（2026-2033 年）的复合年增长率为 5.5%。

全球关节内粘稠补充疗法市场正经历强劲成长，这主要得益于骨关节炎发病率的上升，尤其是在老年人群中。随着对非侵入性治疗方法需求的不断增长，关节内粘稠补充疗法已成为延缓关节重建手术的首选方案。透明质酸配方技术的进步以及微创技术的普及正在推动市场渗透。对维持身体机能的重视、人口老化加剧以及运动伤害的增加进一步推动了市场的动态。然而，高昂的治疗费用、保险覆盖范围的限制以及不同病患小组疗效的差异等挑战，仍然是市场扩张的重要障碍。此外，替代疗法的存在以及各地法规和政策的差异，也可能进一步加剧该领域市场发展的复杂性。

推动全球关节内粘稠补充疗法市场发展的因素

全球关节内粘稠补充疗法市场的主要驱动因素是老年人口中骨关节炎及相关关节疾病盛行率的不断上升。随着人们寿命延长和生活方式日益活跃，对有效疼痛管理方案（例如关节内粘稠补充疗法疗法）的需求也日益增长。这些注射疗法透过增加关节润滑和缓衝作用来缓解疼痛，从而改善活动能力和生活品质。此外，人们健康意识的增强以及对微创治疗方法的偏好也促进了市场扩张，因为患者和医疗保健提供者越来越倾向于寻求传统手术干预之外的关节健康维护方法。

限制全球关节内粘稠补充疗法市场发展的因素

全球关节内粘稠补充疗法市场的主要限制因素之一是透明质酸类产品核准中日益严格的审查和监管挑战。随着医疗监管机构收紧临床疗效和安全性标准，企业面临越来越大的压力，需要证明关节内粘稠补充疗法疗法在治疗骨关节炎及相关疾病方面的长期疗效。这种严格的核准流程可能导致产品上市延迟，研发成本增加，进而抑制创新，限制病患获得新的治疗选择。此外，报销政策的不确定性也会阻碍医疗机构和病患的接受度。

关节内粘稠补充疗法市场的全球趋势

全球关节内粘稠补充疗法市场正经历着向单次注射和长效製剂的显着转变，这主要受便捷高效治疗方法需求成长的驱动。患者和医疗服务提供者越来越倾向于选择单次注射的透明质酸疗法，这种疗法可以减少就诊时间和手术风险，从而提高患者的依从性。同时，长效製剂的推出可望透过持续润滑关节和缓解疼痛来改善治疗效果。这一趋势反映了门诊护理的更广泛变革，强调在骨关节炎治疗中采用更具成本效益的方法，同时满足患者对微创、高效治疗方案日益增长的需求。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Sanofi SA（France）
Anika Therapeutics, Inc.（United States）
SEIKAGAKU CORPORATION（Japan）
Zimmer Biomet Holdings, Inc.（United States）
Bioventus Inc.（United States）
Fidia Farmaceutici SpA（Italy）
Ferring Pharmaceuticals（Switzerland）
Johnson & Johnson（United States）
Smith & Nephew plc（United Kingdom）
Avanos Medical, Inc.（United States）
LG Chem, Ltd.（South Korea）
IBSA Institut Biochimique SA（Switzerland）
Hoffmann-La Roche Ltd.（Switzerland）
Teva Pharmaceutical Industries Ltd.（Israel）
Viatris Inc.（United States）
Lifecore Biomedical, LLC（United States）
Aptissen SA（Switzerland）
Chugai Pharmaceutical Co., Ltd.（Japan）
Kolon TissueGene, Inc.（South Korea）
TRB CHEMEDICA SA（Switzerland）

结论与建议

简介目录

Product Code: SQMIG35B2276

Global Viscosupplementation Market size was valued at USD 5.1 billion in 2024 and is poised to grow from USD 5.38 billion in 2025 to USD 8.26 billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global viscosupplementation market is witnessing robust growth, propelled by the rising incidence of osteoarthritis, particularly among the elderly population. As demand for non-invasive treatments surges, viscosupplementation has become a preferred option for delaying joint replacement surgeries. Advances in hyaluronic acid formulations and a shift toward minimally invasive techniques are enhancing market adoption. The emphasis on maintaining physical mobility, coupled with an increasing elderly demographic and a rise in sports-related injuries, is further boosting market dynamics. However, challenges such as high treatment costs, reimbursement hurdles, and variability in effectiveness across different patient groups pose significant barriers to market expansion. Additionally, the presence of alternative treatments and varying regional regulations and reimbursement policies can further complicate market development in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Viscosupplementation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Viscosupplementation Market Segments Analysis

Global Viscosupplementation Market is segmented by Product, Application, Source, End User and region. Based on Product, the market is segmented into Introduction, Single Injection, Three Injection and Five Injection. Based on Application, the market is segmented into Introduction, Knee Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis and Other Applications. Based on Source, the market is segmented into Introduction, Animal Source and Non-Animal Source. Based on End User, the market is segmented into Introduction, Hospitals, Orthopedic Clinics/Ambulatory Surgical Centers (ASCS), Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Viscosupplementation Market

A key market driver for the global viscosupplementation market is the increasing prevalence of osteoarthritis and related joint disorders among the aging population. As individuals live longer and maintain more active lifestyles, the demand for effective pain management solutions, such as viscosupplements, grows. These injectable treatments provide relief by enhancing joint lubrication and cushioning, thus improving mobility and quality of life. Additionally, rising health awareness and a shift toward minimally invasive treatment options contribute to the market's expansion, as patients and healthcare providers seek alternatives to traditional surgical interventions for joint health.

Restraints in the Global Viscosupplementation Market

One significant market restraint for the global viscosupplementation market is the increasing scrutiny and regulatory challenges associated with the approval of hyaluronic acid-based products. As healthcare authorities strengthen their standards for clinical efficacy and safety, companies face heightened pressure to demonstrate the long-term benefits of viscosupplements in treating osteoarthritis and related conditions. This rigorous approval process can lead to delays in product launches and increased costs for research and development, potentially stifling innovation and limiting the availability of new treatment options for patients. Moreover, the uncertainty surrounding reimbursement policies may hinder adoption among healthcare providers and patients alike.

Market Trends of the Global Viscosupplementation Market

The Global Viscosupplementation market is experiencing a significant shift towards single-injection and long-acting formulations, driven by the increasing preference for convenient and efficient treatment options. Patients and healthcare providers are gravitating towards single-injection hyaluronic acid therapies due to their reduced clinic time and procedural risks, enhancing patient compliance. Simultaneously, the introduction of long-acting formulations offers extended joint lubrication and pain relief, leading to improved treatment outcomes. This trend reflects broader changes in outpatient care, highlighting a cost-effective approach to managing osteoarthritis and catering to the growing demand for less invasive and more effective therapeutic solutions.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Viscosupplementation Market Size by Product & CAGR (2026-2033)

Market Overview
Introduction
Single Injection
Three Injection
Five Injection

Global Viscosupplementation Market Size by Application & CAGR (2026-2033)

Market Overview
Introduction
Knee Osteoarthritis
Hip Osteoarthritis
Shoulder Osteoarthritis
Other Applications

Global Viscosupplementation Market Size by Source & CAGR (2026-2033)

Market Overview
Introduction
Animal Source
Non-Animal Source

Global Viscosupplementation Market Size by End User & CAGR (2026-2033)

Market Overview
Introduction
Hospitals
Orthopedic Clinics/Ambulatory Surgical Centers (ASCS)
Retail Pharmacies
Online Pharmacies

Global Viscosupplementation Market Size & CAGR (2026-2033)

North America (Product, Application, Source, End User)
- US
- Canada
Europe (Product, Application, Source, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Application, Source, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Application, Source, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Application, Source, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Anika Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SEIKAGAKU CORPORATION (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zimmer Biomet Holdings, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioventus Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fidia Farmaceutici S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smith & Nephew plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avanos Medical, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LG Chem, Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IBSA Institut Biochimique SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lifecore Biomedical, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptissen SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chugai Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kolon TissueGene, Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TRB CHEMEDICA SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments